跳至主要内容
临床试验/NCT00042549
NCT00042549终止4 期

Biliary Lithotripsy in Combination With Actigall Versus Actigall Monotherapy for the Treatment of Symptomatic Cholesterol Gallstones

Medstone International4 个研究点 分布在 1 个国家目标入组 184 人开始时间: 2002年5月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
184
试验地点
4

研究概览

简要总结

The purpose of this study is to determine the effectiveness and safety of using the Medstone lithotripter to treat single non-calcified gallstones from 4 to 20 mm in diameter.

详细描述

This study is a randomized, single-masked controlled trial in which the combination therapy of lithotripsy and the bile acid drug Actigall is compared to monotherapy with only Actigall. The primary objectives are, 1) To determine whether the use of the Medstone STS Lithotripter system in combination with the orally administered drug Actigall is more effective (as measured by percentages of stone free patients 6 months after randomization) in reducing single non-calcified radiolucent gallstones (from 4 to 20mm in diameter) than use of Actigall alone, and 2) To demonstrate that use of the Medstone lithotripsy system is safe (as measured by incidence of adverse events) for the intended purpose, when operated according to its labeling.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • History of biliary pain
  • Evidence of a single noncalcified, radiolucent gallstone between 4 and 20 mm (inclusive) diameter
  • HIDA scan demonstrating patency of cystic bile duct
  • No cardiac pacemaker
  • No allergy to radioopaque dye, iodine, bile acids
  • No spontaneous or iatrogenic bleeding disorder
  • No current or prior bile duct obstruction, cholangitis, pancreatitis, or cholecystitis
  • Not pregnant

排除标准

  • 未提供

研究者

发起方
Medstone International
申办方类型
Industry

研究点 (4)

Loading locations...

相似试验